Expert Perspectives on Incorporating Targeted Therapies Into Multidisciplinary Management of Advanced Systemic Mastocytosis
  • CME
  • CE

Get up to date on multidisciplinary care of patients with advanced systemic mastocytosis in this interactive text module featuring expert perspectives on diagnosis, classification, treatment selection, and management of toxicities associated with targeted therapies.
Prithviraj Bose, MD
person default
Ilene A. Galinsky, NP
Caitlin R. Rausch, PharmD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Pharmacists: 1.0 contact hour (0.1 CEUs)
Released: April 12, 2022 Expiration: April 11, 2023

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe the pathophysiology of systemic mastocytosis
  • Discuss the classification (subtypes, diagnostic criteria, role of mutation testing, evaluation of organ damage) in patients with suspected systemic mastocytosis
  • Incorporate newer therapies into the management of advanced systemic mastocytosis based on the disease characteristics and molecular profile of the individual
  • Manage adverse events related to newer therapies for patients with advanced systemic mastocytosis


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Blueprint Medicines

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:


Prithviraj Bose, MD

Associate Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Prithviraj Bose, MD, has disclosed that he has receiving consulting fees from AbbVie, Blueprint Medicines, Bristol-Myers Squibb, CTI BioPharma, Incyte, Karyopharm, Novartis, Pharma Essentia, and Sierra Oncology and funds for research support from Astellas, Blueprint Medicines, Bristol-Myers Squibb, Cogent, Constellation, CTI BioPharma, Incyte, Ionis, Kartos, NS Pharma, Pfizer, and Promedior.
Ilene A. Galinsky, NP

Senior Research Program Adult Leukemia Nurse Practitioner
Department of Leukemia
Dana-Farber Cancer Institute/Brigham and Women's Hospital
Boston, Massachusetts

Ilene A. Galinsky, NP, has disclosed that she has received consulting fees from AbbVie, Jazz, Novartis, and Pfizer.
Caitlin R. Rausch, PharmD

Clinical Pharmacy Specialist, Leukemia
Division of Pharmacy
University of Texas MD Anderson Cancer Center
Houston, Texas

Caitlin R. Rausch, PharmD, has no relevant conflicts of interest to report.


Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Rachael M. Andrie, PhD

Scientific Director

Rachael Andrie, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Krista Marcello

Senior Director, Educational Strategy
Hematology and Oncology

Krista Marcello has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This educational program is intended for physicians, nurses, pharmacists, and other healthcare professionals who treat patients with advanced systemic mastocytosis.


The goal of this program is to improve the knowledge and competence of learners to incorporate newer patient-centered therapies into the management of patients with advanced systemic mastocytosis.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-106-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 12, 2022, through April 11, 2023:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Downloadable slideset from Antonio Urbina, MD, on HIV infection in the transgender population, including strategies for improving patient care and PrEP uptake, from Clinical Care Options (CCO)

Antonio E. Urbina, MD Released: September 27, 2022

Antonio Urbina, MD, discusses HIV infection in the transgender population, including strategies for improving patient care and PrEP uptake, from Clinical Care Options (CCO)

Antonio E. Urbina, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: September 27, 2022 Expired: September 26, 2023

Enter the characteristics of your patient with CLL into an online tool from Clinical Care Options (CCO) to see treatment recommendations from 5 experts

Farrukh T. Awan, MD Jennifer R. Brown, MD, PhD Nicole Lamanna, MD Anthony Mato, MD, MSCE Jeff Sharman, MD Released: September 22, 2022

Download these expert-selected slides on anti-BCMA CAR T-cell and bispecific agents for relapsed/refractory myeloma, from Clinical Care Options (CCO).

Noopur Raje, MD Released: September 22, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings